

Review Article

*Mechanisms of Disease*FRANKLIN H. EPSTEIN, M.D., *Editor***HOMOCYSTEINE AND
ATHEROTHROMBOSIS**GEORGE N. WELCH, M.D.,
AND JOSEPH LOSCALZO, M.D., PH.D.

IN 1969, McCully made the clinical observation linking elevated plasma homocyst(e)ine concentrations with vascular disease.¹ He reported autopsy evidence of extensive arterial thrombosis and atherosclerosis in two children with elevated plasma homocyst(e)ine concentrations and homocystinuria. On the basis of this observation, he proposed that elevated plasma homocyst(e)ine (hyperhomocyst(e)inemia) can cause atherosclerotic vascular disease. The term "homocyst(e)ine" is used to define the combined pool of homocysteine, homocystine, mixed disulfides involving homocysteine, and homocysteine thiolactone found in the plasma of patients with hyperhomocyst(e)inemia.

Subsequent investigations have confirmed McCully's hypothesis, and it has recently become clear that hyperhomocyst(e)inemia is an independent risk factor for atherosclerosis and atherothrombosis. Although severe hyperhomocyst(e)inemia is rare, mild hyperhomocyst(e)inemia occurs in approximately 5 to 7 percent of the general population.^{2,3} Patients with mild hyperhomocyst(e)inemia have none of the clinical signs of severe hyperhomocyst(e)inemia or homocystinuria and are typically asymptomatic until the third or fourth decade of life when premature coronary artery disease develops, as well as recurrent arterial and venous thrombosis. Abundant epidemiologic evidence has demonstrated that the presence of mild hyperhomocyst(e)inemia is an independent risk factor for atherosclerosis in the coronary, cerebral, and peripheral vasculature (see below).^{4,5} Although

the molecular mechanism by which homocyst(e)ine or a related metabolite promotes atherothrombosis is unknown, the epidemiologic evidence of the association of hyperhomocyst(e)inemia with atherothrombotic vascular disease is convincing. In this review, we will evaluate the evidence of a relation between elevated plasma homocyst(e)ine concentrations and vascular disease. Potential mechanisms for this effect are also discussed.

HOMOCYST(E)INE METABOLISM

Homocyst(e)ine is a sulfur-containing amino acid formed during the metabolism of methionine. Homocyst(e)ine is metabolized by one of two pathways: remethylation and transsulfuration (Fig. 1). In the remethylation cycle, homocyst(e)ine is salvaged by the acquisition of a methyl group in a reaction catalyzed by methionine synthase.⁶ Vitamin B₁₂ (cobalamin) is an essential cofactor for methionine synthase, N⁵-methyl-tetrahydrofolate is the methyl donor in this reaction, and N⁵,N¹⁰-methylene-tetrahydrofolate reductase functions as a catalyst in the remethylation process.

Under conditions in which an excess of methionine is present or cysteine synthesis is required, homocyst(e)ine enters the transsulfuration pathway. In this pathway, homocyst(e)ine condenses with serine to form cystathionine in a reaction catalyzed by the vitamin B₆-dependent enzyme cystathionine β-synthase.⁶ Cystathionine is subsequently hydrolyzed to form cysteine, which may in turn be incorporated into glutathione or further metabolized to sulfate and excreted in the urine.⁷

**MEASUREMENT OF PLASMA
HOMOCYST(E)INE**

The majority of the clinical studies involving homocyst(e)ine have relied on the measurement of total plasma homocyst(e)ine, which includes homocysteine, mixed disulfides involving homocysteine, homocysteine thiolactone, free homocysteine, and protein-bound homocysteine. Protein-bound (i.e., disulfide-linked) homocysteine accounts for 70 to 80 percent of the total pool.⁸ Normal total plasma homocyst(e)ine concentrations range from 5 to 15 μmol per liter in the fasting state.^{6,9} Kang and co-workers have classified hyperhomocyst(e)inemia as moderate (homocyst(e)ine concentration, 15 to 30 μmol per liter), intermediate (>30 to 100 μmol per liter), and severe (>100 μmol per liter)⁴ on the basis of concentrations measured during fasting.

An oral dose of methionine (100 mg per kilogram of body weight) can be given to persons with sus-

From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, 715 Albany St., W-507, Boston, MA 02118, where reprint requests should be addressed to Dr. Loscalzo.

©1998, Massachusetts Medical Society.




Figure 1. Metabolism of Homocyst(e)ine.

Homocysteine is an amino acid intermediate formed during the metabolism of methionine, an essential amino acid derived from dietary protein. It is metabolized by one of two pathways: remethylation and transsulfuration. In the remethylation cycle, homocysteine is salvaged by acquiring a methyl group in a reaction catalyzed by the vitamin B₁₂-dependent enzyme methionine synthase. The donor in this reaction is *N*⁵-methyltetrahydrofolate, and the enzyme *N*⁵,*N*¹⁰-methylene-tetrahydrofolate reductase functions as a catalyst in the remethylation cycle. Under conditions in which excess methionine is present or cysteine synthesis is required, homocysteine enters the transsulfuration pathway. In the transsulfuration pathway, homocysteine condenses with serine to form cystathionine in a reaction catalyzed by the vitamin B₆-dependent rate-limiting enzyme cystathionine β-synthase. Cystathionine is subsequently hydrolyzed to form cysteine, which may in turn be incorporated into glutathione or further metabolized to sulfate and excreted in the urine.

pected hyperhomocyst(e)inemia who have normal homocyst(e)ine concentrations during fasting.¹⁰ Plasma homocyst(e)ine concentrations are determined before the methionine challenge and between four and eight hours afterward.¹⁰ Hyperhomocyst(e)inemia is considered to be present if the homocyst(e)ine concentration after methionine challenge is more than 2 SD above the mean.¹⁰ The prognostic value of the methionine-challenge test has recently been criticized¹¹: in persons with the thermolabile variant of *N*⁵,*N*¹⁰-methylene-tetrahydrofolate reductase, there was only a weak association between plasma homocyst(e)ine concentrations after methionine challenge and premature coronary heart disease (odds ratio, 1.7; *P*=0.12), whereas there was a significant association between plasma homocyst(e)ine concentrations during fasting and premature coronary heart disease (odds ratio, 2.0; *P*=0.04). These authors concluded that this enzyme regulates basal homocyst(e)ine concentrations, and thus, its activity can-

not be adequately assessed by a methionine-challenge test. By contrast, enzymes in the transsulfuration pathway are responsible for reversing transient, postprandial increases in the homocyst(e)ine concentration, and their activities can be evaluated by a methionine-challenge test.

GENETIC DEFECTS IN HOMOCYSTEINE METABOLISM

Elevations in plasma homocyst(e)ine are typically caused either by genetic defects in the enzymes involved in homocysteine metabolism or by nutritional deficiencies in vitamin cofactors. Homocystinuria and severe hyperhomocyst(e)inemia are caused by rare inborn errors of metabolism resulting in marked elevations of plasma and urine homocyst(e)ine concentrations. Cystathionine β -synthase deficiency is the most common genetic cause of severe hyperhomocyst(e)inemia. The homozygous form of this disease — congenital homocystinuria — can be associated with plasma homocyst(e)ine concentrations of up to 400 μmol per liter during fasting.¹² The homozygous trait is rare (occurring in 1 in 200,000 births), and clinical manifestations include ectopia lentis, skeletal deformities, mental retardation, thromboembolism, and severe, premature atherosclerosis.¹² Atherothrombotic complications frequently develop in young adulthood in homozygotes and are often fatal, as first shown in a study by Carey and colleagues as early as 1968.¹³ Mudd and colleagues¹⁴ have estimated that approximately 50 percent of untreated patients with homocystinuria will have a thromboembolic event before the age of 30 and that overall, the disease-related mortality is approximately 20 percent. Heterozygotes typically have much less marked hyperhomocyst(e)inemia, with plasma homocyst(e)ine concentrations in the range of 20 to 40 μmol per liter, approximately two to four times greater than the normal concentration of homocyst(e)ine in plasma.^{13,15-17}

A homozygous deficiency of N^5,N^{10} -methylene-tetrahydrofolate reductase, the enzyme involved in the vitamin B_{12} -dependent remethylation of homocysteine to methionine, may also lead to severe hyperhomocyst(e)inemia.¹⁸ Patients with this type of deficiency tend to have a worse prognosis than those with cystathionine β -synthase deficiency, in part because of the complete lack of effective therapy.^{19,20} In addition, Kang and colleagues²¹ have reported a thermolabile variant of N^5,N^{10} -methylene-tetrahydrofolate reductase that is caused by a point mutation (C677T) in the coding region for the N^5,N^{10} -methylene-tetrahydrofolate binding site, leading to the substitution of valine for alanine.²² This mutation was found in 38 percent of French Canadians and 5 to 15 percent of the general population in Canada and correlated with elevated plasma homocyst(e)ine concentrations.^{22,23} Although this variant of the N^5,N^{10} -methylene-tetrahydrofolate reductase gene is quite common, it does not appear to be a significant, independent risk factor for atherothrombotic vascular disease.²⁴⁻²⁶ Persons who are homozygous for this mutation appear to have an exaggerated hyperhomocyst(e)inemic response to the depletion of folic acid and with folic

acid depletion may be at increased risk for vascular disease.²⁶ Other abnormalities of the remethylation cycle that are associated with hyperhomocyst(e)inemia include methionine synthase deficiency and disorders of vitamin B_{12} metabolism that impair methionine synthase activity.

NUTRITIONAL DEFICIENCIES CAUSING HYPERHOMOCYST(E)INEMIA

Nutritional deficiencies in the vitamin cofactors (folate, vitamin B_{12} , and vitamin B_6) required for homocysteine metabolism may promote hyperhomocyst(e)inemia. Markedly elevated homocyst(e)ine concentrations have been observed in patients with nutritional deficiencies of the essential cofactor vitamin B_{12} ²⁷ and the cosubstrate folate.^{28,29} Negative correlations between serum vitamin B_{12} , folate, and vitamin B_6 concentrations and plasma homocyst(e)ine concentrations have been observed in normal subjects.³⁰ Selhub and colleagues³⁰ have suggested that inadequate plasma concentrations of one or more B vitamins are contributing factors in approximately two thirds of all cases of hyperhomocyst(e)inemia. Vitamin supplementation can normalize high homocyst(e)ine concentrations (see below); however, it remains to be determined whether normalizing homocyst(e)ine concentrations will improve cardiovascular morbidity and mortality.

OTHER CAUSES OF HYPERHOMOCYST(E)INEMIA

A number of other factors influence homocyst(e)ine metabolism, including several disease states and medications. Plasma homocyst(e)ine concentrations increase with elevations in creatinine and are typically elevated in chronic renal failure, often approaching concentrations that are up to four times the normal value.^{31,32} Although plasma homocyst(e)ine concentrations often decrease after dialysis,³² it is unclear whether the elevation in homocyst(e)ine observed in end-stage renal disease is due to impaired metabolism or to reduced excretion. The presence of elevated plasma homocyst(e)ine concentrations may partially explain the observed acceleration of atherosclerosis in end-stage renal disease.

A number of reports have linked hyperhomocyst(e)inemia to hypothyroidism,³ suggesting a potential mechanism for the higher incidence of vascular disease observed in patients with hypothyroidism. Hyperhomocyst(e)inemia has also been reported in patients with pernicious anemia, and elevated plasma homocyst(e)ine concentrations are helpful in diagnosing this disorder. In one study of 434 patients with cobalamin deficiency, approximately 96 percent had serum homocyst(e)ine concentrations that were more than 3 SD above the

mean.³³ It is unclear whether these patients are at increased risk for vascular events.

Elevated homocyst(e)ine concentrations have been reported in association with several types of carcinoma, including breast, ovarian, and pancreatic cancer.³⁴ Transformed cells in culture are unable to use homocyst(e)ine, and it has been suggested that proliferating tumor cells may also be incapable of metabolizing endogenous homocysteine.^{2,34} In addition, acute lymphoblastic leukemia is associated with marked elevations in plasma homocyst(e)ine; after chemotherapy for this disorder, homocyst(e)ine concentrations decrease dramatically.^{34,35}

Several drugs and toxins increase plasma homocyst(e)ine concentrations. Methotrexate depletes folate, the cosubstrate for methionine synthase, and causes a transient increase in plasma homocyst(e)ine concentrations.^{2,36} Phenytoin also interferes with folate metabolism and may cause mild hyperhomocyst(e)inemia.^{2,36} Theophylline, a phosphodiesterase inhibitor, may cause hyperhomocyst(e)inemia by antagonizing the synthesis of pyridoxal phosphate (vitamin B₆).³⁷ Cigarette smoking also interferes with the synthesis of pyridoxal phosphate,³⁸ and it has recently been reported that smokers have significantly lower pyridoxal phosphate concentrations than nonsmokers.³⁹ These results suggest another important mechanism whereby smoking may promote atherogenesis.

ASSOCIATION BETWEEN HYPERHOMOCYST(E)INEMIA AND ATHEROSCLEROSIS

Since McCully hypothesized that elevated plasma homocyst(e)ine concentrations could cause atherosclerosis, abundant epidemiologic evidence from more than 20 case-control and cross-sectional studies involving over 2000 patients^{36,40} has validated this relation. Boers and colleagues⁴¹ screened 75 patients with premature atherosclerotic vascular disease for hyperhomocyst(e)inemia using methionine challenge and found that nearly one third of all patients with cerebrovascular disease and peripheral vascular disease had hyperhomocyst(e)inemia. Clarke and colleagues⁴² subsequently measured homocyst(e)ine concentrations after methionine loading in a cohort of men with premature vascular disease and normal controls and demonstrated that 42 percent of patients with cerebrovascular disease, 28 percent of patients with peripheral vascular disease, and 30 percent of patients with coronary artery disease had hyperhomocyst(e)inemia. Clarke et al. also found that the relative risk of coronary artery disease in patients with hyperhomocyst(e)inemia was approximately 24 times that in controls.

Two large, prospective studies have assessed the risk of coronary artery disease in patients with hyperhomocyst(e)inemia. In the Physicians' Health Study, 14,916 male physicians without known ath-

erosclerosis had an initial homocyst(e)ine measurement and were prospectively followed for an average of five years.⁵ Men with plasma homocyst(e)ine concentrations that were 12 percent above the upper limit of normal had approximately a threefold increase in the risk of myocardial infarction, as compared with those with lower levels, even after correction for other risk factors. The authors estimated that 7 percent of the 271 observed myocardial infarctions could be attributed to hyperhomocyst(e)inemia. The prospective design of the study eliminated the possibility that atherosclerosis itself may have altered homocyst(e)ine concentrations. The prospective Trømsø study⁴³ reported similar results, and several other prospective studies have consistently indicated that hyperhomocyst(e)inemia is an independent risk factor for vascular disease.⁴⁴⁻⁴⁶

Selhub and colleagues⁴⁷ have recently demonstrated that the prevalence of carotid-artery stenosis increases with increasing plasma concentrations of homocyst(e)ine. In a cross-sectional study of 1041 elderly subjects in the Framingham Heart Study, they found a strong association between elevated homocyst(e)ine concentrations and occlusive vascular disease that remained even after adjustment for other conventional coronary risk factors. There was a graded, rather than a threshold, relation between plasma homocyst(e)ine and the risk of carotid stenosis. The risk of carotid stenosis was increased even at lower plasma concentrations of homocyst(e)ine (between 11.4 and 14.3 μmol per liter) that had previously been considered to be normal. Malinow and colleagues⁴⁸ reported similar results in an earlier study. A graded response has also been demonstrated between homocyst(e)ine concentrations and the risk of coronary artery disease or cerebrovascular accident.^{5,49-51}

Graham and coworkers⁵² recently measured plasma homocyst(e)ine concentrations in 750 patients with atherosclerosis and 800 normal subjects. There was a statistically significant difference in plasma homocyst(e)ine concentrations during fasting between patients and controls (11.25 μmol per liter vs. 9.73 μmol per liter, $P < 0.001$), and a methionine challenge revealed that an additional 27 percent of patients had hyperhomocyst(e)inemia. Interestingly, an elevated plasma homocyst(e)ine concentration conferred an independent risk of vascular disease similar to that of smoking or hypercholesterolemia and also had a multiplicative effect on risk among cigarette smokers and patients with hypertension.⁵² The authors therefore suggested that controlling hypertension and smoking may be particularly important in patients with hyperhomocyst(e)inemia.

Nygård and colleagues⁵³ recently reported a prospective study involving 587 patients with angiographically documented coronary artery disease. Baseline homocyst(e)ine measurements were obtained,

and patients were followed for a median of 4.6 years, during which time 10.9 percent of them died. These investigators found a strong, graded association between plasma homocyst(e)ine concentrations and overall mortality. The relation between homocyst(e)ine and mortality was strongest for total homocyst(e)ine concentrations above 15 μmol per liter. The adjusted mortality ratio was 1.6 for patients with homocyst(e)ine concentrations of 15 μmol per liter, as compared with those with values of 10 μmol per liter. However, total homocyst(e)ine concentrations were only weakly associated with the extent of coronary artery disease in this study. This study and other key studies designed to evaluate the relation between plasma homocyst(e)ine concentrations and atherothrombotic risk are summarized in Table 1.

In a recent meta-analysis, Boushey and colleagues⁵⁴ estimated that 10 percent of the risk of coronary artery disease in the general population is attributable to homocyst(e)ine. They reported that an increase of 5 μmol per liter in the plasma homocyst(e)ine concentration raises the risk of coronary artery disease by as much as an increase of 20 mg per deciliter (0.52 mmol per liter) in the cholesterol concentration. They suggested that increasing folate consumption by approximately 200 μg per day would reduce total homocyst(e)ine concentrations by approximately 4 μmol per liter, a reduction that could potentially have a major effect on cardiovascular mortality. Randomized clinical trials will be necessary to demonstrate the clinical utility of this strategy. Importantly, the current fortification program will increase folate consumption by approximately

half this amount, and it remains to be seen whether this dietary supplementation of folate will affect the prevalence of coronary heart disease in the general population.

Den Heijer and colleagues⁵⁵ have demonstrated that mild hyperhomocyst(e)inemia is also an independent risk factor for venous thromboembolism. They found a marked increase in the risk of venous thrombosis at the highest plasma homocyst(e)ine concentrations. A plasma homocyst(e)ine concentration of more than 22 μmol per liter increased the matched odds ratio for deep venous thrombosis to 4.0. It is unknown whether homocyst(e)ine-lowering therapy reduces the risk of venous thrombosis in patients with such high concentrations. Recently, Ridker and associates⁵⁶ showed that the combination of hyperhomocyst(e)inemia and factor V Leiden further increases the relative risk of venous thromboembolism up to 3.6-fold.

TREATMENT OF HYPERHOMOCYST(E)INEMIA

The treatment of hyperhomocyst(e)inemia varies with the underlying cause; however, vitamin supplementation (with folic acid, pyridoxine, and vitamin B₁₂) is generally effective in reducing homocyst(e)ine concentrations. The minimal effective doses of folic acid and pyridoxine have not yet been determined. In most patients, small doses of folate (1 to 5 mg per day) rapidly decrease homocyst(e)ine concentrations.⁵⁷ Folic acid alone, folic acid combined with vitamins B₁₂ and B₆, and vitamins B₆ and B₁₂ have all been shown to reduce homocyst(e)ine con-

TABLE 1. MAJOR OBSERVATIONAL STUDIES OF HOMOCYST(E)INE AS A RISK FACTOR FOR ATHEROTHROMBOTIC DISEASE.*

REFERENCE	STUDY DESIGN	MAIN END POINT	MEAN HOMOCYST(E)INE CONCENTRATION		RELATIVE RISK (95% CI)	P VALUE
			CASE PATIENTS	CONTROLS		
			$\mu\text{mol/liter}$			
Taylor et al. ⁴⁶	Case-control	Progression of CAD, CVD, or PVD	14.37±6.89	10.10±2.16	NA	<0.05
Graham et al. ⁵²	Case-control	CAD, CVD, PVD	11.25	9.73	1.9 (1.4-2.4)	<0.001
Stampfer et al. ⁵	Nested case-control	Acute MI or death from cardiovascular causes	11.1±4.0	10.5±2.8	3.4 (1.3-8.8)	0.026
Verhoef et al. ⁴⁵	Nested case-control	Ischemic CVA	11.1±4.0	10.6±3.4	1.2 (0.7-2.0)	0.12
Arnesen et al. ⁴³	Nested case-control	Development of CAD	12.7±4.7	11.3±3.7	1.32 (1.05-1.65)	0.002
Perry et al. ⁵¹	Nested case-control	CVA	13.7	11.9	NA	0.004
Nygård et al. ⁵³	Prospective, observational	Overall mortality, extent of CAD	Males, 11.4 Females, 10.5	NA	NA	0.005† 0.02‡

*Plus-minus values are means ±SD. CI denotes confidence interval, CAD coronary artery disease, CVD cerebrovascular disease, PVD peripheral vascular disease, NA not available, MI myocardial infarction, and CVA cerebrovascular accident.

†The P value is for the trend in the relative risk of stroke as a function of quartiles of plasma homocyst(e)ine concentration.

‡The P value is for the trend in the relative risk of death as a function of plasma homocyst(e)ine concentration.

centrations.⁵⁸ Normalization of the plasma homocyst(e)ine concentration usually occurs within four to six weeks after the initiation of therapy, but may occur in as little as two weeks. Interestingly, the reduction in mortality from cardiovascular causes since 1960 has been correlated with the increase in vitamin B₆ supplementation in the food supply.³

PATHOPHYSIOLOGIC MECHANISMS OF HYPERHOMOCYST(E)INEMIA

Experimental evidence suggests that the atherogenic propensity associated with hyperhomocyst(e)inemia results from endothelial dysfunction and injury followed by platelet activation and thrombus formation. Studies in humans and animals demonstrate that homocyst(e)ine-induced atherosclerosis is characterized by substantial platelet accumulation and platelet-rich thrombus formation in areas of endothelial injury.⁵⁹⁻⁶¹ Harker and colleagues have proposed that homocyst(e)ine-induced endothelial injury exposes the subendothelial matrix, which in turn leads to platelet activation.^{59,60} Lentz and colleagues⁶² have demonstrated that diet-induced hyperhomocyst(e)inemia in primates leads to impaired vasomotor regulation in vivo and endothelial antithrombotic function ex vivo. These findings are supported by the work of Celermajer and colleagues,⁶³ who demonstrated impaired endothelium-dependent vasodilation, and also by van den Berg and colleagues,⁶⁴ who demonstrated impaired endothelial anticoagulant function in young patients with hyperhomocyst(e)inemia and peripheral vascular disease. Although the exact mechanism of endothelial dysfunction is unknown, there is growing evidence that homocyst(e)ine exerts its effects by promoting oxidative damage.

Homocyst(e)ine is rapidly auto-oxidized when added to plasma, forming homocystine, mixed disulfides, and homocysteine thiolactone (Fig. 2).⁶⁵⁻⁶⁷ Potent reactive oxygen species, including superoxide and hydrogen peroxide, are produced during the auto-oxidation of homocyst(e)ine, and hydrogen peroxide (along with the hydroxyl radical), in particular, has been implicated in the vascular toxicity of hyperhomocyst(e)inemia.⁶⁸ There is extensive evidence that homocyst(e)ine-induced endothelial-cell injury in vitro is largely due to the generation of hydrogen peroxide.⁶⁹⁻⁷¹ Harker and colleagues⁵⁹ have proposed that homocyst(e)ine-induced endothelial-cell injury mediated by hydrogen peroxide exposes the underlying matrix and smooth-muscle cells, which in turn proliferate and promote the activation of platelets and leukocytes.

Auto-oxidation of homocyst(e)ine produces other cytotoxic reactive oxygen species, including the superoxide anion radical and hydroxyl radical.^{72,73} Superoxide-dependent formation of the hydroxyl radical has been shown to initiate lipid peroxidation,⁷³




Figure 2. Postulated Adverse Vascular Effects of Homocyst(e)ine.

The postulated effects involve oxidative damage to vascular endothelial cells and increased proliferation of vascular smooth-muscle cells after oxidative metabolism of homocysteine to homocystine and homocysteine thiolactone. Oxidative modification of low-density lipoprotein (LDL) promotes the formation of foam cells, which in turn yields another source of reactive oxygen species.

an effect that occurs at the level of the endothelial plasma membrane and within lipoprotein particles.^{74,75} Homocyst(e)ine auto-oxidation has been shown to support the oxidation of low-density lipoprotein through the generation of the superoxide anion radical.^{74,76}

Although the precise molecular mechanism is unknown, homocyst(e)ine causes endothelial dysfunction at several levels. Homocyst(e)ine alters the normal antithrombotic phenotype of the endothelium by enhancing the activities of factor XII⁷⁷ and factor V⁷⁸ and depressing the activation of protein C.⁷⁹ Homocyst(e)ine also inhibits the expression of thrombomodulin,⁸⁰ induces the expression of tissue factor,⁸¹ and suppresses the expression of heparan sulfate by the endothelium.⁸² All of these effects ultimately

facilitate the formation of thrombin and create a prothrombotic environment.

The production of endothelial-derived nitric oxide is also adversely affected by homocyst(e)ine. Our group⁶⁶ has previously shown that normal endothelial cells detoxify homocyst(e)ine by releasing nitric oxide, which combines with homocysteine in the presence of oxygen to form *S*-nitroso-homocysteine. Nitrosation of the sulfhydryl group of homocysteine inhibits sulfhydryl-dependent generation of hydrogen peroxide.⁶⁶ *S*-nitroso-homocysteine is also a potent platelet inhibitor and vasodilator.⁸³ This protective effect of nitric oxide is eventually compromised as long-term exposure to hyperhomocyst(e)inemia damages the endothelium sufficiently to limit nitric oxide production. Impaired endothelial production of nitric oxide leaves the endothelium vulnerable to unopposed homocyst(e)ine-mediated oxidative injury.⁶⁶ Homocyst(e)ine may also decrease the bioavailability of nitric oxide by impairing its synthesis.^{68,75} Homocyst(e)ine promotes lipid peroxidation, which may subsequently decrease the expression of endothelial nitric oxide synthase and directly degrade nitric oxide.⁸⁴⁻⁸⁶ Our group has recently shown that homocysteine (but not cysteine) suppresses the expression of cellular glutathione peroxidase by endothelial cells, and this effect promotes lipid peroxidation by the reactive oxygen species elaborated during the oxidation of homocysteine.⁸⁷

In addition to promoting atherosclerosis through endothelial injury or dysfunction, homocyst(e)ine is also a potent mitogen for vascular smooth-muscle cells. Harker and colleagues⁸⁸ demonstrated that infusion of homocyst(e)ine into baboons results in the formation of atheromata. Exposure to homocyst(e)ine leads to a marked increase in vascular smooth-muscle proliferation *in vitro*, an effect that is due in part to an increase in the expression of messenger RNA of cyclin D1 and cyclin A.⁸⁹ Tsai and coworkers⁹⁰ have proposed that homocyst(e)ine promotes atherogenesis specifically by inducing the proliferation of vascular smooth-muscle cells.

We have recently demonstrated that homocyst(e)ine increases nitric oxide production in vascular smooth-muscle cells by activating the transcription factor NF- κ B.⁹¹ It appears that NF- κ B is activated by a homocyst(e)ine-generated reactive oxygen species.⁹¹ Since NF- κ B/rel activity is essential for the proliferation of vascular smooth-muscle cells,⁹² these data suggest that homocyst(e)ine-mediated activation of NF- κ B contributes to the mitogenic effect of homocyst(e)ine.

Homocyst(e)ine also directly damages the vascular matrix by affecting the biochemical and biosynthetic functions of vascular cells. Homocysteine thiolactone, a highly reactive anhydrous byproduct of homocysteine oxidation, combines with low-density lipoprotein to form aggregates that are taken up by

intimal macrophages and incorporated into foam cells within nascent atheromatous plaques.⁹³ There is, however, some doubt that the thiolactone can form in sufficient concentrations *in vivo* to evoke these effects. Recently, Jakubowski showed that cells deficient in cystathionine β -synthase produce more homocysteine thiolactone in culture than normal cells and that the thiolactone is incorporated into cellular and secreted proteins through lysine acylation by the activated carboxyl group of the thiolactone.⁹⁴ McCully³ has suggested that in this microenvironment homocysteine thiolactone facilitates the conversion of mitochondrial thioretinaco ozonide to thioco, thereby impairing oxidative phosphorylation and promoting the proliferation and fibrosis of smooth muscles.⁹⁵⁻⁹⁷ This homocyst(e)ine-induced disturbance in oxidative metabolism also leads to overproduction of oxidative radicals that subsequently induce intimal injury, activate elastase, and increase calcium deposition.^{96,98} Homocyst(e)ine may also contribute to the deposition of sulfated glycosaminoglycan in the matrix; it appears that the sulfur group of homocysteine thiolactone is incorporated into phosphoadenosine phosphosulfate, which ultimately leads to the formation of sulfated glycosaminoglycans.⁹⁸

The recently observed multiplicative increase in the risk of vascular disease in the presence of traditional risk factors and hyperhomocyst(e)inemia⁵² may in part be related to the effect of homocyst(e)ine on lipid peroxidation. The vascular cytotoxicity of oxidized low-density lipoprotein has been linked to its content of lipid peroxidation products.^{99,100} Homocyst(e)ine increases the formation of highly atherogenic oxysterols, increases lipid peroxidation, and increases the oxidation of low-density lipoprotein *in vitro*.^{101,102} These observations suggest a potential role for antioxidant therapy in ameliorating homocyst(e)ine-dependent oxidative vascular injury; however, this therapeutic approach has not yet been tested in prospective clinical trials.

CONCLUSIONS

Multiple prospective and case-control studies have shown that a moderately elevated plasma homocysteine concentration is an independent risk factor for atherothrombotic vascular disease. Homocysteine concentrations are consistently higher in patients with peripheral, cerebrovascular, and coronary artery disease than in those without such diseases. Homocyst(e)ine promotes atherothrombogenesis by a variety of mechanisms; however, it is not yet clear whether homocysteine itself or a related metabolite or cofactor is primarily responsible for the atherothrombogenic effects of hyperhomocyst(e)inemia *in vivo*. Before advocating widespread screening of patients with atherosclerotic vascular disease, we must have a clearer understanding of the

clinical efficacy of potential therapeutic interventions. Vitamin supplementation decreases or even normalizes plasma homocyst(e)ine concentrations in most cases. Prospective, randomized clinical trials, however, will be necessary to determine the effect of vitamin supplementation on cardiovascular morbidity and mortality.

Supported in part by grants (HL58976, HL53919, HL55993, and HL48743) from the National Institutes of Health and by a Merit Review Award from the Department of Veterans Affairs.

We are indebted to Adrian Zai for invaluable assistance with the artwork and to Dr. Gilbert R. Upchurch, Jr., for critical review of the manuscript.

REFERENCES

- McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969;56:111-28.
- Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. *J Lab Clin Med* 1989;114:473-501.
- McCully KS. Homocysteine and vascular disease. *Nat Med* 1996;2:386-9.
- Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Ann Rev Nutr* 1992;12:279-98.
- Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *JAMA* 1992;268:877-81.
- Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem* 1993;39:1764-79.
- Finkelstein JD, Martin JJ, Harris BJ. Methionine metabolism in mammals: the methionine-sparing effect of cystine. *J Biol Chem* 1988;263:11750-4.
- Ueland PM. Homocysteine species as components of plasma redox thiol status. *Clin Chem* 1995;41:340-2.
- Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. *Clin Chem* 1994;40:873-81.
- Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy, and enzymology. *Arterioscler Thromb* 1993;13:1253-60.
- Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary disease: evidence for a common gene mutation. *Circulation* 1996;94:2154-8.
- Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. *The metabolic and molecular bases of inherited disease*. 7th ed. Vol. 1. New York: McGraw-Hill, 1995:1279-327.
- Carey MC, Donovan DE, FitzGerald O, McAuley FD. Homocystinuria. I. A clinical and pathological study of nine subjects in six families. *Am J Med* 1968;45:7-25.
- Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β -synthase deficiency. *Am J Hum Genet* 1985;37:1-31.
- Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. *Circulation* 1989;79:1180-8.
- Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. *Stroke* 1990;21:572-6.
- Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson O, Upson B. Homocyst(e)ine in daily practice: levels in coronary heart disease. *Coronary Artery Dis* 1990;2:4-12.
- Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. *Biochem Biophys Res Commun* 1972;46:905-12.
- Erbe RW. Inborn errors of folate metabolism. In: Blakely RL, Whitehead VM, eds. *Folate and pterins: nutritional, pharmacological, and physiological aspects*. New York: Marcel Dekker, 1986:413-25.
- D'Angelo A, Selhub J. Homocysteine and thrombotic disease. *Blood* 1997;90:1-11.
- Kang SS, Zhou J, Wong PWK, Kowalysyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. *Am J Hum Genet* 1988;43:414-21.
- Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995;10:111-3.
- Arruda VR, von Zuben PM, Chiaparin LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677 \rightarrow Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. *Thromb Haemost* 1997;77:818-21.
- Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. *Circulation* 1996;94:2410-6.
- van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. *Circulation* 1997;95:21-3.
- Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. *Circulation* 1996;94:3074-8.
- Brattström L, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B₁₂ deficiency than in heterozygosity for homocystinuria due to cystathionine β -synthase deficiency. *Metabolism* 1988;37:175-8.
- Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. *Metabolism* 1987;36:458-62.
- Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. *J Clin Invest* 1988;81:466-74.
- Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA* 1993;270:2693-8.
- Wilcken DE, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. *Eur J Clin Invest* 1979;9:301-7.
- Chauveau P, Chadeaux B, Coûde M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. *Kidney Int Suppl* 1993;41:S72-S77.
- Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies. *Am J Med* 1994;96:239-46.
- Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *J Am Coll Cardiol* 1996;27:517-27.
- Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. *Cancer Res* 1991;51:828-35.
- Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. *Atherosclerotic cardiovascular disease, hemostasis, and endothelial function*. New York: Marcel Dekker, 1992:183-236.
- Ubbink JB, van der Merwe A, Delport A, et al. The effect of a subnormal vitamin B₆ status on homocysteine metabolism. *J Clin Invest* 1996;98:177-84.
- Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. *JAMA* 1995;274:1526-33.
- Vermaak WJ, Ubbink JB, Barnard HC, Potgieter GM, van Jaarsveld H, Groenewald AJ. Vitamin B₆ nutrition status and cigarette smoking. *Am J Clin Nutr* 1990;51:1058-61.
- Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? *N Engl J Med* 1995;332:328-9.
- Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. *N Engl J Med* 1985;313:709-15.
- Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* 1991;324:1149-55.
- Arnesen E, Refsum H, Bonna KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. *Int J Epidemiol* 1995;24:704-9.
- Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis* 1994;106:9-19.
- Verhoeve P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. *Stroke* 1994;25:1924-30.
- Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. *J Vasc Surg* 1991;13:128-36.
- Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. *N Engl J Med* 1995;332:286-91.
- Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymp-

- tomatic adults: the Atherosclerosis Risk in Communities Study. *Circulation* 1993;87:1107-13.
49. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. *Arterioscler Thromb* 1991;11:1129-36.
 50. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B₁₂ concentrations and risk for early-onset coronary artery disease. *Am J Clin Nutr* 1994;59:940-8.
 51. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet* 1995;346:1395-8.
 52. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. *JAMA* 1997;277:1775-81.
 53. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997;337:230-6.
 54. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-57.
 55. den Hejjer M, Kostor T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *N Engl J Med* 1996;334:759-62.
 56. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. *Circulation* 1997;95:1777-82.
 57. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid — an innocuous means to reduce plasma homocysteine. *Scand J Clin Lab Invest* 1988;48:215-21.
 58. Saltzman E, Mason JB, Jacques PF, et al. B vitamin supplementation lowers homocysteine levels in heart disease. *Clin Res* 1994;42:172A. abstract.
 59. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. *N Engl J Med* 1974;291:537-43.
 60. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. *J Clin Invest* 1976;58:731-41.
 61. James TN. The spectrum of diseases of small coronary arteries and their physiologic consequences. *J Am Coll Cardiol* 1990;15:763-74.
 62. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. *J Clin Invest* 1996;98:24-9.
 63. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. *J Am Coll Cardiol* 1993;22:854-8.
 64. van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. *Eur J Clin Invest* 1995;25:176-81.
 65. Velury S, Howell SB. Measurement of plasma thiols after derivatization with monobromobimane. *J Chromatogr* 1988;424:141-6.
 66. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. *J Clin Invest* 1993;91:308-18.
 67. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. *Clin Chem* 1995;41:361-6.
 68. Welch GN, Upchurch GR Jr, Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. *Ann N Y Acad Sci* 1997;811:48-58.
 69. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. *Thromb Res* 1980;18:113-21.
 70. de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. *Eur J Clin Invest* 1983;13:405-10.
 71. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. *J Clin Invest* 1986;77:1370-6.
 72. Misra HP. Generation of superoxide free radical during the autooxidation of thiols. *J Biol Chem* 1974;249:2151-5.
 73. Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. *FEBS Lett* 1982;138:33-6.
 74. Heinecke JW. Superoxide-mediated oxidation of low density lipoprotein by thiols. In: Cerutti PA, Fridovich I, McCord JM, eds. *Oxy-radicals in molecular biology and pathology*. New York: Alan R. Liss, 1988:443-57.
 75. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. *J Clin Invest* 1996;98:5-7.
 76. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. *J Biol Chem* 1987;262:10098-103.
 77. Ratnoff OD. Activation of Hageman factor by L-homocystine. *Science* 1968;162:1007-9.
 78. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. *J Clin Invest* 1986;77:1909-16.
 79. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. *Blood* 1990;75:895-901.
 80. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. *J Clin Invest* 1991;88:1906-14.
 81. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. *Arterioscler Thromb* 1993;13:1327-33.
 82. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. *J Clin Invest* 1993;92:1381-6.
 83. Stamler JS, Simon DI, Osborne JA, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. *Proc Natl Acad Sci U S A* 1992;89:444-8.
 84. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. *J Clin Invest* 1992;89:10-8.
 85. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. *J Biol Chem* 1995;270:319-24.
 86. Blom HJ, Kleinvelde HA, Boers GH, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. *Eur J Clin Invest* 1995;25:149-54.
 87. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. *J Biol Chem* 1997;272:17012-7.
 88. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. *Circ Res* 1983;53:731-9.
 89. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. *Proc Natl Acad Sci U S A* 1994;91:6369-73.
 90. Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. *J Clin Invest* 1996;97:146-53.
 91. Welch GN, Upchurch GR Jr, Farivar RS, et al. Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF- κ B dependent transcriptional activation of *Nos2*. *Proc Am Assoc Phys* 1998;110:22-31.
 92. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF- κ B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. *J Clin Invest* 1995;96:2521-7.
 93. Naruszewicz M, Mirkiewicz E, Olszewski AJ, et al. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. *Nutr Metab Cardiovasc Dis* 1994;4:70-77.
 94. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. *J Biol Chem* 1997;272:1935-42.
 95. McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. *Ann Clin Lab Sci* 1993;23:477-93.
 96. *Idem*. Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. *Ann Clin Lab Sci* 1994;24:27-59.
 97. *Idem*. Chemical pathology of homocysteine. III. Cellular function and aging. *Ann Clin Lab Sci* 1994;24:134-52.
 98. *Idem*. Homocysteine metabolism in scurvy, growth and arteriosclerosis. *Nature* 1971;231:391-2.
 99. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. *J Lipid Res* 1983;24:1070-6.
 100. Hughes H, Mathews B, Lenz ML, Guyton JR. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. *Arterioscler Thromb* 1994;14:1177-85.
 101. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. *J Lipid Res* 1993;34:2051-61.
 102. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. *Biochim Biophys Acta* 1987;917:337-40.